European Companies Search Engine
EU funding (€15M): Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response. Hor 1 Jan 2019 EU Research and Innovation programme "Horizon"
Overview
Text
Gut OncoMicrobiome Signatures (GOMS) associated with cancer incidence, prognosis and prediction of treatment response.
Beyond the role the intestinal metagenome plays in regulating multiple physBeyond its role in regulating multiple physiological functions that impact health, the intestinal metagenome is implicated in cancer initiation, progression and responses to therapies, even for extraintestinal neoplasia. Hence, there is an urgent need to fully identify and functionally characterize minimalist commensal ecosystems relevant to cancer, with reliable and robust methods, to validate cancer-associated gut microbiome fingerprints of high clinical relevance, and to develop diagnosis tools that will become part of the oncological arsenal for the optimization and personalization of therapy. Based on retro-and pro-spective studies, with large discovery and validation cohorts enrolling >9,000 cancer patients across 10 countries, ancillary to ongoing innovative clinical trials or FDA/EMA approvals across 4 frequent cancer types, ONCOBIOME will pursue the following aims: 1/ identify and validate core or cancer-specific Gut OncoMicrobiome Signatures (GOMS) associated with cancer occurrence, prognosis, response to, or progression on, therapy (polychemotherapy, immune checkpoint inhibitors, dendritic cell vaccines) or adverse effects, 2/ decipher the functional relevance of these cancer-associated gut commensal ecosystems in the regulation of host metabolism, immunity and oncogenesis, 3/ integrate these GOMS with other oncology hallmarks (clinics, genomics, immunomics, metabolomics) 4/ design optimal companion tests, based on those integrated signatures to predict cancer occurrence and progression. With high carat interdisciplinary experts, ONCOBIOME expects to validate cancer or therapy-specific Gut OncoMicrobiome Signatures (GOMS) across breast, colorectal, melanoma and lung cancers adjusting for covariates, to unravel the mode of action of these GOMS in innovative platforms, thus lending support to the design of cancer preventive campaigns using well characterized pre-and pro-biotics.
Funded Companies:
| Company name | Funding amount |
| Algoe SA | €210,612 |
| Centre Hospitalier DE L'Universitede Montreal | €0.00 |
| Charite - Universitaetsmedizin Berlin | €0.00 |
| Everimmune | €519,000 |
| Fondazione Irccs Istituto Nazionale DEI Tumori | €223,750 |
| GBG Forschungs GmbH | €619,313 |
| Gustave Roussy Transfert | €0.00 |
| Iigm Foundation | €887,936 |
| Institut Gustave Roussy | €2,942,215 |
| Institut National de la Sante et de la Recherche Medicale | €898,275 |
| Karolinska Institutet | €2,801,954 |
| Ludwig-Maximilians-Universitaet Muenchen | €434,967 |
| Masarykova Univerzita | €842,296 |
| Masarykuv Onkologicky Ustav | €0.00 |
| Philipps Universitaet Marburg | €703,063 |
| Stichting Radboud Universitair Medisch Centrum | €946,651 |
| Stichting Radboud Universiteit | €15,570.03 |
| The Chancellor Masters and Scholars of the University of Cambridge | €413,386 |
| Unicancer | €431,979 |
| Universita Degli Studi Di Torino | €0.00 |
| Universita Degli Studi Di Trento | €1,603,119 |
| Universitatsklinikum Erlangen | €412,158 |
| Veracyte | €88,309 |
Source: https://cordis.europa.eu/project/id/825410
The filing refers to a past date, and does not necessarily reflect the current state.
